Novartis slips after pelacarsen Phase 3 setback
Novartis traded at $159.99 after pelacarsen flopped in a pivotal Phase 3 cardiovascular trial. Reuters estimated about CHF4.9 billion evaporated from market value as Zurich-listed shares fell 1.9%.
99 Monday after pelacarsen failed in a pivotal Phase 3 cardiovascular trial. 9%. The market’s message was clear: investors were reprice the stock sharply lower after the setback.